Embecta Corp. (EMBC) SEC Filings & Earnings Calls

U.S. revenue decline accelerating (-24.6% YoY) indicates structural demand loss from insulin pen needle competition and GLP-1 shift

“U.S. revenues decreased 24.6% on both a reported and adjusted constant currency basis” · word for word

Gross margin compression of ~10 percentage points (GAAP) driven by mix shift and cost pressures

“Gross profit and margin of $153.3 million and 56.4%, compared to $197.1 million and 66.7% in the prior year period” · word for word

High leverage from acquisition debt; net debt remains significant despite $53M repayment

“Borrowed ~$180 million under the Company's $500 million revolving credit facility to fund the Owen Mumford acquisition; subsequently repaid approximately $53 million of debt” · word for word

Tariff cost pressure

“As a global company that both imports raw materials and products into the U.S. and distributes raw materials and products originating from the U.S. to global manufacturing sites and markets, these tariffs may have a financial impact on our cost of goods, our profit margins, our business generally and our global distribution strategy.” · word for word

Demand decline from new drugs

“Introduction of new drugs and increased penetration of oral and once-weekly anti-diabetic drugs (e.g., SGLT-2s, once-weekly insulin, GLP-1s and GLP-1 combination products) have delayed initiation of insulin therapy and contributed to less demand for our products.” · word for word

Pricing pressure from competition

“We face significant pricing pressures from competitors in the pen needle and insulin syringe categories who not only can provide competitive products at lower costs, but also provide payors and customers with more choices for formulary partners in these categories.” · word for word

Integration risk and earnout dependency on Aidaptus sales milestones.

“Up to £50 million in performance-based payments based on net sales of the Aidaptus® next generation auto-injector platform.”

Tariff risk

“Given our global business, we expect tariffs announced over the past year will result in additional cost for us and our suppliers.” · word for word

Geopolitical risk

“The conflict between the United States, Israel, and Iran and related geopolitical instability may adversely affect our business.” · word for word

Acquisition integration risk

“If we do not successfully integrate the operations of OM as currently anticipated, it could adversely affect our financial condition and results from operations.” · word for word

U.S. business deterioration from competitive dynamics and market softness, leading to significant revenue decline and margin compression.

“U.S. revenues decreased 29.4% on both a reported and adjusted constant currency basis” · word for word

Dividend cut and share repurchase authorization signal financial strain and shift in capital allocation.

“reducing our quarterly cash dividend from $0.15 to $0.01 per share” · word for word

Integration risk from pending Owen Mumford acquisition amid operational challenges.

“pending acquisition of Owen Mumford remains on track to close during May 2026” · word for word

U.S. revenue decline of 7.6% signals potential market share loss or pricing pressure in core domestic market

“U.S. revenues decreased 7.6% on both a reported and adjusted constant currency basis” · word for word

Contract manufacturing revenue down 14.6% indicates reduced non-diabetes product sales to BD

“Contract Manufacturing 4.1 million, down 14.6%”

Tariff cost and competitive risk

“Given our global business, we expect recently announced tariffs will result in additional cost for us and our suppliers, and there is the potential that such tariffs may influence future decisions by foreign governments and private purchasers to source non-U.S., 'locally' manufactured products instead of products originating from certain countries (including” · word for word

GLP-1 demand erosion

“Introduction of new drugs and increased penetration of oral and once-weekly anti-diabetic drugs (e.g., SGLT-2s, once-weekly insulin, GLP-1s and GLP-1 combination products) have delayed initiation of insulin therapy and contributed to less demand for our products.” · word for word

Pricing pressure from commoditization

“We face significant pricing pressures from competitors in the pen needle and insulin syringe categories who not only can provide competitive products at lower costs, but also provide payors and customers with more choices for formulary partners in these categories.” · word for word

High debt leverage

“Total debt $1,362.4 million; weighted average cost 6.1%; significant maturities in 2029 ($653.2M) and 2030 ($700M).”

Revenue headwinds from FX and pricing concessions

“The Adjusted Constant Currency Revenue $ target was below prior year results. This year over year reduction was due in part to FX headwinds... and anticipated pricing concessions related to the renewal of certain customer agreements whose terms were expiring.” · word for word

Patch pump program discontinuation costs

“Early in the year, we discontinued our patch pump program and implemented restructuring initiatives that improved profitability” · word for word

Product concentration risk

“For the fiscal year ended September 30, 2025, sales of pen needles accounted for approximately $784 million, or 73%, of total net revenues.” · word for word

Single-source supply risk (cannula from BD)

“In connection with our separation from Becton, Dickinson and Company ("BD") in 2022 (the “Separation”), we entered into a cannula supply agreement with BD, whereby BD sells to us cannulas for incorporation into our pen needles and syringes.” · word for word

Customer concentration risk

“For the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta’s three largest distributors, together represented approximately 42% of Embecta’s worldwide gross sales.” · word for word

Competitive threat from GLP-1s and alternative therapies

“competitors, including pharmaceutical companies, also offer, or are attempting to develop, alternative therapies, including oral and once-weekly anti-diabetic drugs (e.g., SGLT-2s, once-weekly insulin, GLP-1s, and GLP-1 combination products), for disease states (including diabetes) that may be administered and delivered less frequently compared to convention” · word for word

Tariff and trade policy risk

“The current tariff environment evolves continuously and is uncertain. The United States has imposed tariffs and export controls on certain goods and products imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries.” · word for word

Revenue decline driven by advanced distributor ordering and China business dynamics.

“Revenue lower year over year due to several items we had previously anticipated, including the impact of advanced distributor ordering...and the continuing business dynamics in China.” · word for word

Geopolitical and trade environment remains dynamic, posing risks to global operations.

“While the broader geopolitical and trade environment remains dynamic.” · word for word

Board turnover may signal governance instability, but resignations are voluntary and not due to disagreements.

“Two directors leaving; one immediate resignation, one not standing for re-election; both cite personal reasons.”